Nuvectis Pharma (NASDAQ:NVCT) Issues Quarterly Earnings Results, Misses Expectations By $0.05 EPS

Nuvectis Pharma (NASDAQ:NVCT) announced its quarterly earnings results on Wednesday. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.05), FiscalAI reports.

Nuvectis Pharma Stock Performance

Shares of NVCT stock opened at $8.70 on Thursday. Nuvectis Pharma has a 1 year low of $5.55 and a 1 year high of $11.52. The business’s fifty day moving average is $8.10 and its 200-day moving average is $6.93. The stock has a market cap of $222.68 million, a PE ratio of -6.35 and a beta of -0.29.

Wall Street Analysts Forecast Growth

NVCT has been the topic of several recent research reports. Weiss Ratings restated a “sell (e+)” rating on shares of Nuvectis Pharma in a report on Thursday, January 22nd. HC Wainwright reissued a “buy” rating on shares of Nuvectis Pharma in a research note on Wednesday, December 3rd. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $15.33.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of NVCT. Police & Firemen s Retirement System of New Jersey acquired a new position in Nuvectis Pharma in the second quarter valued at about $28,000. Oppenheimer & Co. Inc. grew its stake in Nuvectis Pharma by 6.5% in the fourth quarter. Oppenheimer & Co. Inc. now owns 73,566 shares of the company’s stock valued at $555,000 after purchasing an additional 4,500 shares in the last quarter. JPMorgan Chase & Co. increased its stake in shares of Nuvectis Pharma by 3,398.9% during the 2nd quarter. JPMorgan Chase & Co. now owns 6,263 shares of the company’s stock worth $47,000 after purchasing an additional 6,084 shares during the last quarter. Bank of America Corp DE raised its stake in Nuvectis Pharma by 417.2% in the second quarter. Bank of America Corp DE now owns 8,565 shares of the company’s stock valued at $64,000 after buying an additional 6,909 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in Nuvectis Pharma in the 2nd quarter valued at $53,000. 96.77% of the stock is currently owned by institutional investors and hedge funds.

Nuvectis Pharma Company Profile

Nuvectis Pharma is a clinical-stage biotechnology company focused on the development of novel peptide-based therapeutics using its proprietary Cellporting delivery platform. The company’s core technology is designed to facilitate the transport of therapeutic proteins and peptides across cellular membranes and into target intracellular compartments, including the nucleus. By overcoming a key barrier in biologics delivery, Nuvectis aims to expand the range of treatable diseases with macromolecular drugs that have traditionally been limited by poor cellular uptake.

The Nuvectis pipeline encompasses multiple preclinical and early-stage clinical programs targeting rare genetic and metabolic disorders.